Evidence map›Paper›PMID 32228796›Full record

ArticleThe American journal of tropical medicine and hygiene2020

Post-Treatment Surveillance for Lymphatic Filariasis in Plateau and Nasarawa States, Nigeria: Results of Transmission Assessment Surveys.

Abel Eigege, Gregory S Noland, Solomon E Adelamo, Kenrick Nwodu, Adamu Sallau, John Umaru, Bulus S Mancha, Emmanuel Davies, Jacob Danboyi, Jonathan A Kadimbo and 4 more

Abstract read
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Abel EigegeThe Carter Center, Jos, Nigeria.
Gregory S NolandThe Carter Center, Atlanta, Georgia.
Solomon E AdelamoThe Carter Center, Jos, Nigeria.
Kenrick NwoduThe Carter Center, Jos, Nigeria.
Adamu SallauThe Carter Center, Jos, Nigeria.
John UmaruThe Carter Center, Jos, Nigeria.
Bulus S ManchaThe Carter Center, Jos, Nigeria.
Emmanuel DaviesFederal Ministry of Health, Abuja, Nigeria.
Jacob DanboyiState Ministry of Health, Lafia, Nasarawa.
Jonathan A KadimboState Ministry of Health, Jos, Plateau.
Yisa A SakaFederal Ministry of Health, Abuja, Nigeria.
Ifeoma AnagboguFederal Ministry of Health, Abuja, Nigeria.
Emmanuel S MiriThe Carter Center, Jos, Nigeria.
Frank O RichardsThe Carter Center, Atlanta, Georgia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following the halt of mass drug administration (MDA) for lymphatic filariasis (LF), the WHO recommends at least 4 years of post-treatment surveillance (PTS) to confirm that transmission recrudescence or importation does not occur. The primary means of evaluation during PTS is repeated transmission assessment surveys (TASs) conducted at 2- to 3-year intervals after TAS-1 stop-MDA surveys. This study reports the results of TAS-2 and TAS-3 surveys in Plateau and Nasarawa states (pop. 6.9 million) of Nigeria divided into a minimum of seven evaluation units (EUs) per TAS. A total of 26,536 first- and second-year primary school children (approximately 6-7 years old) were tested for circulating filarial antigen (CFA) between 2014 and 2017. Of 12,313 children tested in TAS-2 surveys, only five (0.04%) were CFA positive, with no more than two positive samples from any one EU, which was below the critical value of 20 per EU. Of 14,240 children tested in TAS-3 surveys, none (0%) were CFA positive. These results indicate that LF transmission remains below sustainable transmission levels and suggest that elimination of transmission has been achieved in Plateau and Nasarawa, Nigeria.

Indexed as

Mass Drug AdministrationPopulation SurveillanceAlbendazoleAnthelminticsChildChild, PreschoolElephantiasis, FilarialFemaleFilaricidesHumansIvermectinMaleNigeriaRetrospective StudiesAlbendazoleAnthelminticsFilaricidesIvermectin

Identifiers

PMID32228796
PMCPMC7253131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.